Abstract
Integrating tumor heterogeneity in the drug discovery process is a key challenge to tackle breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is particularly important to tailor therapy to the heterogeneous tumor subpopulations. For this purpose, we performed an unsupervised, label-free, spatially resolved shotgun proteogenomic guided by MALDI mass spectrometry imaging (MSI) on 124 selected tumor clonal areas from early luminal breast cancers, tumor stroma, and breast cancer metastases. 2868 proteins were identified. The main protein classes found in the clonal proteome dataset were enzymes, cytoskeletal proteins, membrane-traffic, translational or scaffold proteins, or transporters. As a comparison, gene-specific transcriptional regulators, chromatin related proteins or transmembrane signal receptor were more abundant in the TCGA dataset. Moreover, 26 mutated proteins have been identified. Similarly, expanding the search to alternative proteins databases retrieved 126 alternative proteins in the clonal proteome dataset. The majority of these alternative proteins were coded mainly from non-coding RNA. To fully understand the molecular information brought by our approach and its relevance to drug target discovery, the clonal proteomic dataset was further compared to the TCGA breast cancer database and two transcriptomic panels, BC360 (nanoString®) and CDx (Foundation One®). We retrieved 139 pathways in the clonal proteome dataset. Only 55% of these pathways were also present in the TCGA dataset, 68% in BC360 and 50% in CDx. Seven of these pathways have been suggested as candidate for drug targeting, 22 have been associated with breast cancer in experimental or clinical reports, the remaining 19 pathways have been understudied in breast cancer. Among the anticancer drugs, 35 drugs matched uniquely with the clonal proteome dataset, with only 7 of them already approved in breast cancer. The number of target and drug interactions with non-anticancer drugs (such as agents targeting the cardiovascular system, metabolism, the musculoskeletal or the nervous systems) was higher in the clonal proteome dataset (540 interactions) compared to TCGA (83 interactions), BC360 (419 interactions), or CDx (172 interactions). Thus, we described the non-redundant knowledge brought by this approach compared to TCGA or transcriptomic panels, the targetable proteins identified in the clonal proteome dataset, and the potential of this approach for drug discovery and repurposing through drug interactions with antineoplastic agents and non-anticancer drugs.
Significance Spatially resolved mass spectrometry guided by MALDI MS imaging is a precision oncology tool to map and profile breast cancer proteomic clones with the aim of integrating tumor heterogeneity in the target discovery process to develop clone-tailored therapeutic strategies in breast cancer.
Highlights
Spatially resolved mass spectrometry guided by MALDI mass spectrometry imaging allows an in-depth proteomic profiling of breast cancer functional clones.
This unsupervised and unlabeled technology performed on intact tumors provides a multidimensional analysis of the clonal proteome including conventional proteins, mutated proteins, and alternative proteins.
The rich clonal proteomic information generated was not redundant with TCGA or transcriptomic panels, and showed pathways exclusively found in the proteomic analysis.
A large proportion of the proteins in the clonal proteome dataset were druggable with both antineoplastic agents and non-anticancer drugs, showing the potential application to drug repurposing.
A significant number of the proteins detected had partially or not yet known drug interactions, showing the potential for discovery.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This work was funded by Inserm and Centre Oscar Lambret.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate: All the analyses of this retrospective study were approved by the local Research and Ethics Committee (Centre Oscar Lambret) in accordance with the French and European legislation. Prior to the analyses, patients signed an informed consent and authorization form for the use of their data and biological samples. No personal information was used in these experiments, and a random number was assigned to each sample.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw data are available as supplementary material files and on ProteomeXchange with identifier PXD024134.
Abbreviations
- ABC
- advanced breast cancer
- ACN
- acetonitril
- AGC
- automatic gain control
- AltProt
- alternative proteins
- ANOVA
- analysis of variance
- ATC
- anatomical therapeutic chemical
- BC
- breast cancer
- Da
- dalton
- DMFS
- distant metastases free survival
- EBC
- early breast cancer
- EMA
- european medicines agency
- FDA
- food and drug administration
- FDR
- false discovery rate
- FFPE
- formalin-fixed paraffin-embedded
- HCCA
- hydroxycinnamic acid
- HER2
- human epidermal growth factor receptor-2
- HR
- hazard ratio
- HUGO
- human genome organization
- ID
- identification
- IDG
- illuminating the druggable genome
- IDG-KMC
- illuminating the druggable genome knowledge management center
- ITO
- indium tin oxide
- LC
- liquid chromatography
- LESA
- liquid extraction surface analysis
- LFQ
- label-free quantification
- MALDI
- matrix assisted laser desorption ionization
- MeOH
- methanol
- Meta
- metastases
- MS
- mass spectrometry
- MSI
- mass spectrometry imaging
- OS
- overall survival
- PMDA
- pharmaceuticals and medical devices agency
- PSM
- peptide spectrum matches
- SNP
- single nucleotide polymorphism
- TDL
- target development level
- TFA
- trifluoroacetic acid
- TIC
- total ion count